CTNNBL1 and neoplasm: In contrast, no additional benefit was observed for the NAP-armed SFV virus (SFV-GD2m-NAP) in NXS2 tumor-bearing mice (Figures 5E and 5F), and equal levels of anti-GD2 antibodies were induced after SFV-GD2m and SFV-GD2m-NAP treatments (Figure 6B).